文献速递炎症性肠病

系统综述:美沙拉秦在溃疡性结肠炎中的安全性

Systematic review: safety of mesalazine in ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2018-05-03

该系统综述检索MEDLINE数据库至2017年12月1日,最终纳入91项研究,总结美沙拉秦相关不良事件包括炎症反应、胰腺炎、心脏毒性、肝毒性、肌肉骨骼症状、呼吸系统症状、肾病和性功能障碍;未发现剂量依赖关系,高剂量(>2.4 g/天)与低剂量(≤2.4 g/天)安全性相似。

要点

  • 美沙拉秦相关不良事件涉及炎症反应、胰腺炎、心脏毒性、肝毒性、肌肉骨骼症状、呼吸系统症状、肾病和性功能障碍。
  • 高剂量(>2.4 g/天)与低剂量(≤2.4 g/天)美沙拉秦的安全性相似,未发现剂量依赖关系。
  • 使用美沙拉秦前应评估基线和肾功能,肾功能需定期监测,其他检查根据症状出现进行。

核心结论

  • 美沙拉秦高剂量(>2.4 g/天)与低剂量(≤2.4 g/天)的安全性相似,未发现与不良事件风险增加相关。

研究设计与样本

  • 系统综述,检索MEDLINE数据库从建库至2017年12月1日的相关研究,由两名评价者独立筛选文献、评估偏倚风险并提取数据。
  • 初始检索到3581篇文章,筛选3573篇,综述622篇,最终纳入91项研究。

主要发现

  • 美沙拉秦相关不良事件包括炎症反应、胰腺炎、心脏毒性、肝毒性、肌肉骨骼症状、呼吸系统症状、肾病和性功能障碍。
  • 未发现美沙拉秦与不良事件发生之间存在剂量依赖关系。

关键数值与推荐

  • 高剂量定义为>2.4 g/天,低剂量定义为≤2.4 g/天。

临床怎么用

  • 使用美沙拉秦的患者应监测溃疡性结肠炎是否加重以及是否出现新发的器官功能障碍。
  • 在开始美沙拉秦治疗前,应评估基线和肾功能。
  • 肾功能应定期评估,其他检查应根据症状出现情况进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mesalazine is the most commonly prescribed medication for mild to moderate ulcerative colitis. It is generally well tolerated with some reported side effects. AIM: To summarise adverse drug events to mesalazine and recommend techniques for management. Furthermore, to determine if there is a dose-dependent relationship between high (>2.4 g/day) vs low dosing (≤2.4 g/day) and occurrence of adverse drug events. METHODS: A literature search for relevant studies from inception to 1 December 2017 of the MEDLINE database was conducted. Two reviewers screened all titles identified. Data obtained from randomised controlled trials was used to estimate incidence rates of each adverse event. Two reviewers independently assessed methodological risk of bias and performed data extraction. RESULTS: 3581 articles were initially considered. Of these, 3573 were screened, 622 reviewed and 91 included. Adverse events attributed to mesalazine included inflammatory reactions, pancreatitis, cardiotoxicity, hepatotoxicity, musculoskeletal complaints, respiratory symptoms, nephropathies and sexual dysfunction. There does not appear to be a dose-dependent relationship of mesalazine and occurrence of adverse events. CONCLUSION: Patients on mesalazine should be monitored for worsening of ulcerative colitis and development of new onset organ dysfunction. High-dose mesalazine appears to have similar safety profile as low dose, and is not associated with greater risk of adverse events. Prior to placing a patient on mesalazine, baseline liver and renal function should be evaluated. Renal function should be periodically assessed, whereas other testing should be performed depending on development of symptoms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sehgal P, Colombel JF, Aboubakr A, et al. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018. PMID: 29722441. doi:10.1111/apt.14688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。